NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

BillionToOne, Inc. (BLLN) Stock Analysis

BillionToOne, Inc. (BLLN) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

BLLN

$99.39

−$0.11 (−0.11%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BLLN with… →

BLLN Key Statistics

As of Sep 4, 2026
Trading
Open
$97.84
Previous Close
$99.50
Day's Range
96.14–100.72
52-Week Range
61.96–150.44
Volume
976.40K
Valuation
Market Cap
$4.69B
P/E Ratio
138.04
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
66.93
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
11.80
EPS (ttm)Profit attributable to each share over the last twelve months.
0.72
Financials (FY)
Revenue (FY)
$305.11M
Net Income (FY)
$7.45M
Profit marginThe share of revenue left as profit after all costs and taxes.
8.35%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
42.64M
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
732.75K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BLLN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+21.44%
2025 (partial year)−24.88%

As of September 4, 2026.

BLLN Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricBLLNDiagnostics & Research medianvs median
P/E138.0433.084.2x the median
P/S ratio11.804.99136% above
Profit margin8.35%0.00%8.3 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values BillionToOne, Inc. (BLLN) at $4.69B. The company sits in the Healthcare sector, in the Diagnostics & Research industry. Headcount on file is 713.

Over the past 52 weeks the price has ranged from $61.96 to $150.44. The most recent close on file for BLLN is $99.39, dated September 4, 2026. That is −$0.11 (−0.11%) against the previous close. The latest close sits 60.41% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $305.11M. The same year closed with net income of $7.45M. The reported profit margin is 8.35%. That is 8.3 percentage points above the Diagnostics & Research median of 0%. Trailing earnings per share are 0.72.

Valuation Assessment

On trailing earnings, the shares are priced at 138.04 times earnings. That is 4.2 times the Diagnostics & Research median of 33.08. On forward earnings the ratio is 66.93. Measured against sales, the shares trade at 11.8 times revenue. On price-to-sales that is 136.48% above the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

The stored price history starts on November 6, 2025, and the total return since then is −8.77%.

Growth & Income

The record shows no dividend for BLLN.

2026 is still running; the price is +21.44% year to date.

Peer Comparison

BillionToOne, Inc. (BLLN) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BillionToOne, Inc. BLLN $4.69B 138.0
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. BillionToOne, Inc. trades at a P/E of 138.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About BillionToOne, Inc.

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Visit website →